secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2021-07-23T23:59:59+00:00
Accession:  0001104659-21-095443
Event type: leadership
Sentiment:  negative
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Therapeutics announces resignation of Chief Development Officer Reina Benabou effective July 30, 2021
--------------------------------------------------------------------------------

- Reina Benabou, M.D., Ph.D., Chief Development Officer, tendered resignation effective July 30, 2021.
- No successor or interim appointment announced in the filing.
- Benabou was a named executive officer in the company's April 2021 proxy statement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465921095443/0001104659-21-095443-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465921095443/tm2122742d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-095443

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer